BioAtla, Inc. (NASDAQ:BCAB) Sees Large Increase in Short Interest

BioAtla, Inc. (NASDAQ:BCAB) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 5,240,000 shares, a growth of 17.2% from the September 30th total of 4,470,000 shares. Based on an average trading volume of 1,180,000 shares, the short-interest ratio is presently 4.4 days.

BioAtla Price Performance

Shares of BCAB stock opened at $2.04 on Wednesday. The stock has a market cap of $98.61 million, a P/E ratio of -0.92 and a beta of 1.06. The company has a fifty day moving average price of $1.86 and a two-hundred day moving average price of $1.90. BioAtla has a one year low of $1.14 and a one year high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. During the same quarter last year, the firm posted ($0.75) EPS. As a group, equities research analysts anticipate that BioAtla will post -1.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a report on Monday, September 16th.

Institutional Trading of BioAtla

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of BioAtla during the 1st quarter worth about $45,000. Vontobel Holding Ltd. bought a new position in BioAtla during the third quarter worth about $28,000. Chicago Partners Investment Group LLC bought a new position in BioAtla in the 3rd quarter valued at about $44,000. Ground Swell Capital LLC bought a new position in BioAtla in the 2nd quarter valued at about $33,000. Finally, Valmark Advisers Inc. bought a new position in BioAtla in the 2nd quarter valued at about $34,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.